Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q2 FY21 Earnings Presentation
25 slides from Rossari Biotech's earnings presentation, Oct 25, 2020
Slide 1: Rossari – Q2 FY21 Earnings Presentation cover letter
ROSSARI making you rnore competitive October 25, 2020 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Ltd. First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Plot No.C/1, 'G'Block Phiroze Jeejeebhoy Towers Bandra- Kurla Complex Dalal Street, Fort Bandra E
Slide 2: Rossari Biotech Limited Q2 & H1 FY21 Results Presentation
Rossari Biotech Limited Q2 & H1 FY21 Results Presentation October 24, 2020
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward- looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to
Slide 4: Q2 & H1 FY21 Results Overview
Q2 & H1 FY21 Results Overview
Slide 5: Q2 FY21 – Key Financial Highlights
Q2 FY21 – Key Financial Highlights Revenue from Operations EBITDA PAT (Rs. crore) (Rs. crore) (Rs. crore) 30.1 20.7 * 171.7 28.3 150.3 17.7 23.7 15.5 109.5 Q2 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q1 FY21 Q2 FY21 Q2 FY20 Q1 FY21 Q2 FY21 Shift % (Y-o-Y) 14.2% Shift % (Y-o-Y) 6.2% Shift % (Y-o-Y) 16.9% Shift %
Slide 6: Management Message
Management Message Commenting on the performance for the quarter, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We are pleased to share that we have delivered a robust performance during the quarter driven by improve
Slide 7: Key Developments
Key Developments Rossari Centre of Excellence, the Company’s second R&D laboratory, fully operationalised During the quarter, the Company’s new state-of-the-art certified R&D laboratory, Rossari Centre of Excellence was fully operationalised. Strategically located on the IIT campus in Mumbai, the
Slide 8: Key Developments
Key Developments The Board of Directors appoint Mr. Manikantan Viswanathan as Group Chief Financial Officer (CFO) of the Company Mr. Manikantan Viswanathan has been appointed as the Group CFO of Rossari with effect from 26th October, 2020. He is a Chartered Accountant by profession and has extensi
Slide 9: Consolidated P&L Statement
Consolidated P&L Statement Y-o-Y Change Y-o-Y Change Particulars (Rs. crore) Q2 FY21 Q2 FY20 H1 FY21 H1 FY20 (%) (%) Revenues from Operations 171.7 150.3 14.2% 281.1 278.1 1.1% Total Expenditure 14.2 12.2 16.1% 22.7 22.8 -0.9% • Raw Material expenses 108.1 89.3 21.0% 171.8 169.9 1.1% • Employee bene
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet EQUITY AND LIABILITIES CONSOLIDATED CONSOLIDATED ASSETS CONSOLIDATED CONSOLIDATED As on 30th September As at 31st March 2020 As on 30th September As at 31st March 2020 Particulars (Rs. crore) Particulars (Rs. crore) 2020 (Audited) 2020 (Audited) EQUITY ASSETS Equity Share
Slide 11: Consolidated Cash Flows
Consolidated Cash Flows Cash Flow CONSOLIDATED CONSOLIDATED Cash Flow CONSOLIDATED CONSOLIDATED For the half year ended 30th For the half year ended For the half year ended 30th For the half year ended Particulars (Rs. crore) September, 2020 30th September, 2019 Particulars (Rs. crore) September, 20
Slide 12: Q2 FY21 - Segment-wise Details
Q2 FY21 - Segment-wise Details Segment-wise Revenue Break-up (Rs. crore) HPPC TSC AHN 83.5 87.7 66.7 70.9 68.3 12.7 17.3 15.6 8.7 Q2 FY20 Q1 FY21 Q2 FY21 HPPC TSC AHN Shift (Y-o-Y) % 31.5% -3.7% 22.8% Shift (Q-o-Q) % 5.1% 295.2% 80.2% Key Highlights: The Company continued to witness momentum in th
Slide 13: Q2 FY21 - Financial and Operational Discussions (Y-o-Y)
Q2 FY21 - Financial and Operational Discussions (Y-o-Y) Net Revenues Revenues from operations stood at Rs. 171.7 crore from Rs. 150.3 crore As the country moved to the un-lockdown phase, the Company witnessed encouraging pick-up in demand and consumption across business segments. This, resulted in
Slide 14: Q2 FY21 - Financial and Operational Discussions (Y-o-Y)
Q2 FY21 - Financial and Operational Discussions (Y-o-Y) Balance Sheet The Company utilized the IPO proceeds towards funding its working capital requirements, prepayment of loans and for general corporate purposes As on September 30, 2020, the Company is debt-free Cashflows from operating activ
Slide 15: Key Balance Sheet Parameters
Key Balance Sheet Parameters Particulars ( Rs. crore) As on September 30, 2020 As on March 31, 2020 Net Worth (Rs. crore) 363.6 286.7 Gross Block* (Rs. crore) 150.6 108.2 Net Debt / (Cash) (Rs. crore) (102.3) 61.0 Net Working Capital (Days) 47 34 - Inventory (Days) 53 35 - Receivable (Days) 57 57 -
Slide 16: Conference Call Details
Conference Call Details Q2 & H1 FY21 Earnings Conference Call Time • 05:00 p.m. IST on Monday, October 26, 2020 Primary dial-in number • + 91 22 6280 1141 / 7115 8042 India Local access Number • +91 70456 71221 (Available all over India) • Hong Kong: 800 964 448 International Toll Free Number • Sing
Slide 17: Company Overview
Company Overview
Slide 18: Company Overview
Company Overview Technocrat promoters with 45+ 2 120,000 2 42% 60% cumulative years of Manufacturing MTPA* R&D Facilities: Revenue CAGR % PAT CAGR % experience in the locations: Production capacity Silvassa, Gujarat & IIT (FY18-20) (FY18-20) speciality chemicals industry Silvassa and Dahej, at Silva
Slide 19: Customer Centric and Sustainability Focused R&D Capabilities
Customer Centric and Sustainability Focused R&D Capabilities Two R&D Formulations facilities: Silvassa and Rossari Rich experience Synthesis & across the Centre for Research Development Excellence - IIT business leading Mumbai to expertise in formulation and development Integrated Capabilities Techn
Slide 20: Expansion of Manufacturing Capacity
Expansion of Manufacturing Capacity Total Capacity Manufacturing Facility at Silvassa (‘000 MTPA) 2.1x Expansion of 132.5 capacity from Located on 8.6 acres of land 120,000 to 252,500 MTPA Fungible manufacturing capabilities for powders, 80 120 120 granules and liquids 60 Facility has a compre
Slide 21: Experienced Promoters and Board of Directors
Experienced Promoters and Board of Directors Founders & Promoters Independent Directors B. Sc. (chemistry major) from K. J. Somaiya College of Completed her basic education from Lawrence School Lovedale, University Science, University of Bombay & B. Sc. (technology) in Meher of Cambridge textile
Slide 22: Proven Track Record of Robust Financial Performance
Proven Track Record of Robust Financial Performance Revenue from Operations (INR cr) Operational leverage driving higher margins FY18 FY19 FY20 CAGR: 42% EBITDA (INR cr) EBITDA Margin (%) PAT (INR cr) PAT Margin (%) 299 17.5% 10.9% Total 516 600 14.3% 15.0% 8.5% 8.8% 29 AHN 52 57 214 TSC 269 262 55
Slide 23: Key Strengths
Key Strengths Diversified product portfolio Providing intelligent and sustainable chemical solutions for customers across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Wide sales and distribution network Chemicals, Performance Chemicals, the Animal Health and Nutrition an
Slide 24: Strategic Growth Levers
Strategic Growth Levers Augmenting product portfolio with enhanced emphasis on green solutions Increase wallet share across existing customer base while also tapping new customer segments Identifying and developing new niches in product offerings by leveraging R&D capabilities Capitalize on cros
Slide 25: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a For further information, please contact: Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Manasi Nisal Headquartered at Mumbai, India, the Company operates 2